-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sjögren's syndrome (SS) is a systemic autoimmune disease involving not only the exocrine glands but also multiple systems such as the kidneys, lungs or nerves
.
Janus kinases (JAKs) play critical roles in many cytokine signaling pathways in the pathogenesis of SS , including the type I interferon (IFN) pathway, interleukin (IL)-6 , IL-17 , IL-12 , and IL-23 .
Sjögren's syndrome (SS) is a systemic autoimmune disease involving not only the exocrine glands but also multiple systems such as the kidneys, lungs or nerves
In this pilot study, investigators investigated the efficacy and safety of baricitinib in patients with active SS .
Eleven patients were recruited who met the 2016 American College of Rheumatology / European League Against Rheumatism (EULAR) classification criteria for primary SS with moderate or high disease activity, defined as EULAR primary SS Disease Activity Index ( ESSDAI) ≥ 5 .
ESSDAI , EULAR Patient Reportable Index for Primary SS (ESSPRI) , Physician's Global Assessment (PGA) score and serological measures including erythrocyte sedimentation rate (ESR) , IgG levels, and remission of organ manifestations were assessed .
Response to treatment or minimal clinically important progression ( MCII ), defined as at least a three-point reduction in ESSDAI .
After baricitinib treatment, ESSDAI scores decreased significantly ( 10.
0 ± 4.
6 vs 3.
4 ± 4.
4 , p<0.
After baricitinib treatment, ESSDAI scores decreased significantly ( 10.
0 ± 4.
6 vs 3.
4 ± 4.
In this study, baricitinib improved arthritis and rash symptoms in patients with SS, and may be effective and well tolerated in patients with SS-ILD .
Patients with a history of HBV infection should pay more attention to the risk of hepatitis B recurrence due to the effect of baricitinib on IFN inhibition .
Further high-quality randomized controlled clinical trials are needed to confirm the therapeutic benefit of baricitinib in SS .
Source: Bai W, Liu H, Dou L , et al .
Pilot study of baricitinib for active Sjogren's syndrome.
Annals of the Rheumatic DiseasesPublished Online First: 25 March 2022.
doi: 10.
Bai W, Liu H, Dou L , et al .
leave a message here
